Navigation Links
The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Date:2/19/2013

PSAs and print advertising. According to Lisa Stockmon , senior vice president, marketing at LLS, "Our objective is to build brand awareness so people have more knowledge of what we do and the impact of what we do. We're telling our story in a humanistic and modern way that engages our 62 chapters and also provides a marketing umbrella for The Leukemia & Lymphoma Society, because we want to make sure people have an emotional connection and are aware of our role in the battle against blood cancers."

For more information on "Someday is Today" visit http://www.lls.org/somedayistoday/. LLS is also on Facebook and Twitter

LLS Fundraising Campaigns:  Something for Everyone

LLS fundraising campaigns reflect its broad approach to attracting individual and corporate donors, with a range of entry points and opportunities for participation. From the inception in 1988 of Team In Training®, the world's first and largest endurance training program, to the inspirational, community-oriented Light The Night® Walk events, to the family-friendly Pineapple Classic obstacle course, LLS has an extraordinary range of programs dedicated to raise awareness, participation and, most important, funds to develop and provide access to blood cancer treatments. All 62 LLS chapters in the United States and Canada are dedicated to this mission.

Innovating with Venture Philanthropy: Therapy Acceleration Program™ (TAP)

LLS launched the Therapy Acceleration Program (TAP) in 2007, to advance development of new therapies and diagnostics by bridging the gap between discovery and human applications, and to increase the likelihood that novel, even breakthrough treatments will be available to patient
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
2. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
3. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
4. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
5. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
6. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
9. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
10. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
(Date:9/22/2014)... have generated a new star-shaped molecule made up of interlocking ... created. , Known as a ,Star of David, ... a quarter of a century and the team,s findings are ... Consisting of two molecular triangles, entwined about each other three ... each triangle is 114 atoms in length around the ...
(Date:9/22/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... current state of the M-Phenylenediamine (mPDA) industry in ... of the industry, including definitions, applications and industry chain ... are provided with a focus on history, developments, trends ... the international and Chinese situation is also offered. , ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 ... desire to stay young has groomed and nurtured ... industry worldwide. Growing emphasis on appearance maintenance is ... is a neurotoxic protein obtained from the bacterium, ... resulting in muscle relaxation. With cosmetic indications for ...
Breaking Biology Technology:Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 2Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 3
... Boston Scientific,Corporation (NYSE: BSX ) today announced financial ... as guidance for net sales and,earnings per share (EPS) for ... -- Reported net sales of $1.978 billion and adjusted ... market leadership -- Achieved worldwide cardiac rhythm management (CRM) ...
... Holding Company to Strengthen ... Acquires Research and Product Development Company to Expedite Product ... ... at 8:00 am E.T., NEW YORK, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, ...
... $165 Million Line of Credit to ... Amylin, ... ) and Eli Lilly and Company (NYSE: LLY ),today announced they have ... if approved, would,become the first once weekly therapy to treat type 2 diabetes. ...
Cached Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27American Oriental Bioengineering Completes Two Acquisitions 2American Oriental Bioengineering Completes Two Acquisitions 3American Oriental Bioengineering Completes Two Acquisitions 4Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 2Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 3
(Date:9/21/2014)... protein therapy that disrupts the process that causes cancer ... through the blood stream and start aggressive new growths ... metastasis, can cause cancer to spread with deadly effect. ... cancer fall prey to metastatic forms of the disease," ... describes a new therapeutic approach in Nature Chemical ...
(Date:9/19/2014)... the unique bioelectric signaling system of the electric fish, ... The OU researcher is working to understand how these ... used to map the world around them. Electric ... discharges a second throughout their lives. The energetic ... necessary for survival. , "There is evidence that electric ...
(Date:9/19/2014)... which over thousands of years has adapted to the arctic ... makes the cold dangerous for you. , This is happening ... the cold provoking substance, called nonylphenol, comes from the use ... of being a endocrine disruptor, but when entering the worm ... to protect the cells in its body from cold damage. ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... have just provided the medical community a new way of ... of life forms and functions. University of Central Florida ... to analyze RNA motifs the subunits that make up ... building blocks of life along with DNA and proteins. ...
... stem cell study conducted in mice suggests a novel ... a heart attack. The approach potentially could improve cardiac ... new blood vessels and avoid the risk of ... the journal PLoS ONE , ( http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0030329 ) ...
... Biology Organization (EMBO) and the Federation of European ... the Friedrich Miescher Institute for Biomedical Research in ... FEBS/EMBO Women in Science Award. Professor Gasser has ... genome stability and epigenetics and her commitment to ...
Cached Biology News:Stem cell study in mice offers hope for treating heart attack patients 2Stem cell study in mice offers hope for treating heart attack patients 3Susan M. Gasser to receive the 2012 FEBS/EMBO Women in Science Award 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Request Info...
... Bean Nuclease catalyzes the degradation of single-stranded ... terminated products. While the nuclease prefers ssDNA ... concentrations the enzyme degrades double-stranded DNA from ... been used for transcript mapping studies (3,4), ...
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
Biology Products: